Elevance Health (NYSE:ELV) Price Target Raised to $495.00

by · The Markets Daily

Elevance Health (NYSE:ELV – Free Report) had its price objective lifted by TD Cowen from $465.00 to $495.00 in a report published on Friday, MarketBeat Ratings reports. TD Cowen currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $451.00 target price on shares of Elevance Health in a report on Friday. Leerink Partners increased their price target on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Barclays increased their price target on Elevance Health from $469.00 to $472.00 and gave the stock an “overweight” rating in a report on Thursday. Raymond James Financial set a $450.00 price target on Elevance Health in a research report on Tuesday, July 7th. Finally, Morgan Stanley lifted their price objective on Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a report on Thursday. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $455.57.

View Our Latest Research Report on ELV

Elevance Health Stock Up 0.0%

Shares of NYSE ELV opened at $440.05 on Friday. The stock has a market cap of $95.08 billion, a P/E ratio of 18.77, a P/E/G ratio of 2.10 and a beta of 0.70. The firm has a 50 day moving average price of $408.32 and a 200 day moving average price of $391.51. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. Elevance Health has a 52-week low of $274.84 and a 52-week high of $450.69.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping the consensus estimate of $4.71 by $2.28. The company had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period last year, the business posted $6.03 earnings per share. Analysts expect that Elevance Health will post 29.11 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.

Insiders Place Their Bets

In related news, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This represents a 34.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.34% of the company’s stock.

Institutional Trading of Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of ELV. Activest Wealth Management raised its position in Elevance Health by 146.2% in the 3rd quarter. Activest Wealth Management now owns 64 shares of the company’s stock valued at $25,000 after buying an additional 38 shares during the last quarter. Kilter Group LLC bought a new stake in Elevance Health in the 2nd quarter valued at approximately $28,000. WealthCollab LLC lifted its stake in Elevance Health by 42.2% in the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after acquiring an additional 27 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in Elevance Health by 600.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after acquiring an additional 90 shares during the last quarter. Finally, Tacita Capital Inc acquired a new position in Elevance Health during the 2nd quarter worth approximately $44,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

  • Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
  • Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
  • Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
  • Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
  • Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
  • Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
  • Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
  • Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

See Also